---
figid: PMC6721565__cancers-11-01162-g003
figtitle: LRP6 and WNT/Beta-catenin pathway alterations in epithelial cancers
organisms:
- Nicotiana tabacum
- Lareunionomyces loeiensis
- Hepatitis B virus
- Mouse mammary tumor virus
- Homo sapiens
- Mus musculus
- Xenopus laevis
- Helicobacter pylori
organisms_ner:
- Homo sapiens
- Mus musculus
- Xenopus laevis
- Danio rerio
pmcid: PMC6721565
filename: cancers-11-01162-g003.jpg
figlink: /pmc/articles/PMC6721565/figure/cancers-11-01162-f003/
number: F3
caption: LRP6 and WNT/β-catenin pathway alterations in epithelial cancers. (A) In
  colorectal cancer (CRC), LRP6 overexpression is observed in 61% of malignant tissues
  isolated from patients. (i) Mutations in the E3 ubiquitin-protein ligase RNF43,
  (ii) downregulation of the antagonist DKK1 and (iii) overactivation of the RAS/MAPK
  pathway result in the recruitment of degradation complex components at the membrane
  and WNT/β-catenin pathway overactivation. (B) In hepatocellular carcinomas (HCCs),
  LRP6 is overexpressed in 45%–75% of HCC tumours. Downregulation of miR-126-3p, miR-202
  and single-nucleotide polymorphism of miR-1269 result in increased LRP6 mRNA stability
  and protein levels. The long non-coding RNA FOX2-ASI, upregulated in HCC, targets
  and downregulates DKK1 mRNA (LRP6 inhibitor), thus increasing LRP6 membrane levels.
  (C) In breast cancers (BCs), LRP6 overexpression is observed in 20%–36% of carcinomas,
  and β-catenin nuclear accumulation is reported in 40%–60% of cases. (D) In pancreatic
  ductal adenocarcinoma (PDAC), (i) mutations of RNF43 are observed in 5%–10% of PDAC
  patients, (ii) down-regulation of miR-454 and (iii) upregulation of LINC01133—a
  long non-coding RNA which induces DKK1 promoter methylation (decreasing DKK1 expression)—all
  explain increased LRP6 expression and subsequent increased β-catenin-dependent signaling.
papertitle: A Role for the WNT Co-Receptor LRP6 in Pathogenesis and Therapy of Epithelial
  Cancers.
reftext: Jennifer Raisch, et al. Cancers (Basel). 2019 Aug;11(8):1162.
year: '2019'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9662753
figid_alias: PMC6721565__F3
figtype: Figure
redirect_from: /figures/PMC6721565__F3
ndex: d10e4b2f-ded0-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6721565__cancers-11-01162-g003.html
  '@type': Dataset
  description: LRP6 and WNT/β-catenin pathway alterations in epithelial cancers. (A)
    In colorectal cancer (CRC), LRP6 overexpression is observed in 61% of malignant
    tissues isolated from patients. (i) Mutations in the E3 ubiquitin-protein ligase
    RNF43, (ii) downregulation of the antagonist DKK1 and (iii) overactivation of
    the RAS/MAPK pathway result in the recruitment of degradation complex components
    at the membrane and WNT/β-catenin pathway overactivation. (B) In hepatocellular
    carcinomas (HCCs), LRP6 is overexpressed in 45%–75% of HCC tumours. Downregulation
    of miR-126-3p, miR-202 and single-nucleotide polymorphism of miR-1269 result in
    increased LRP6 mRNA stability and protein levels. The long non-coding RNA FOX2-ASI,
    upregulated in HCC, targets and downregulates DKK1 mRNA (LRP6 inhibitor), thus
    increasing LRP6 membrane levels. (C) In breast cancers (BCs), LRP6 overexpression
    is observed in 20%–36% of carcinomas, and β-catenin nuclear accumulation is reported
    in 40%–60% of cases. (D) In pancreatic ductal adenocarcinoma (PDAC), (i) mutations
    of RNF43 are observed in 5%–10% of PDAC patients, (ii) down-regulation of miR-454
    and (iii) upregulation of LINC01133—a long non-coding RNA which induces DKK1 promoter
    methylation (decreasing DKK1 expression)—all explain increased LRP6 expression
    and subsequent increased β-catenin-dependent signaling.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - LRP6
  - FZD1
  - FZD10
  - FZD2
  - FZD3
  - FZD4
  - FZD5
  - FZD6
  - FZD7
  - FZD8
  - FZD9
  - DKK1
  - RNF43
  - AXIN1
  - AXIN2
  - CHKA
  - DVL1
  - DVL1P1
  - DVL2
  - DVL3
  - IFT81
  - APC
  - PROC
  - KRAS
  - HRAS
  - NRAS
  - MTG1
  - CTNNB1
  - EPHB2
  - MAPK1
  - MAPK3
  - BRAF
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - FOXD2-AS1
  - MIR202
  - MIR1269A
  - CSNK1A1
  - KRT1
  - CSNK1A1L
  - LINC01133
  - MIR454
  - ZHX2
  - ARAF
  - RAF1
  - WNT1
  - WNT2
  - WNT2B
  - WNT3
  - WNT3A
  - WNT4
  - WNT6
  - WNT7A
  - WNT7B
  - WNT8A
  - WNT8B
  - WNT9A
  - WNT9B
  - WNT10A
  - WNT10B
  - WNT11
  - WNT16
  - WNT5A
  - WNT5B
  - Lrp6
  - Dkk1
  - Rnf43
  - Axin1
  - Dvl1
  - Apc
  - ras
  - Hras
  - Kras
  - Rem1
  - Ctnnb1
  - Ephb2
  - Mapk1
  - Braf
  - Braf-rs1
  - Mdk
  - Mir202
  - Gm12892
  - dm
  - Zhx2
  - lrp6.L
  - lrp6.S
  - dkk1.S
  - dkk1.L
  - axin1.S
  - csnk1g2.L
  - dvl2.L
  - dvl2.S
  - apc.L
  - kirsten-ras
  - kras.L
  - hras.L
  - krasl.L
  - kras.S
  - ctnnb1.S
  - ctnnb1.L
  - mapk1.L
  - mapk1.S
  - braf.S
  - snrpe.S
  - snrpe.L
  - braf.L
  - csnk1a1.L
  - krt8.1.S
  - csnk1a1.S
  - krt8.1.L
  - raf1.S
  - lrp6
  - lrp5
  - dkk1b
  - rnf43
  - cki
  - apc
  - rab1ab
  - kras
  - ctnnb1
  - braf
  - si:dkey-222f8.3
  - mir202
  - Cancer
  - Cardiomyopathy
  - Noonan syndrome
---
